Skip to content

Hemodynamic Stability in Septic Shock Patients Undergoing Continuous Renal Replacement Therapy With oXiris Membrane

Real-time Monitoring of Hemodynamic Stability in Septic Shock Patients Undergoing Continuous Renal Replacement Therapy: Propensity Score-matched Comparison Between oXiris and Polysulfone Membranes

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05575024
Acronym
HISTORIX
Enrollment
98
Registered
2022-10-12
Start date
2024-01-01
Completion date
2026-12-31
Last updated
2025-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury Due to Sepsis

Brief summary

The new adsorbing membrane for continuous renal replacement therapy (CRRT), oXiris, can reduce plasma cytokines and endotoxins in septic shock patients with severe acute kidney injury, compared with standard membranes. However, its hemodynamic stability or benefits have not been thoroughly evaluated although this is reasonable.

Detailed description

The new adsorbing membrane for continuous renal replacement therapy (CRRT), oXiris, can reduce plasma cytokines and endotoxins in patients with severe acute kidney injury or sepsis, compared with standard membranes. Based on this benefit, the use of oXiris may confer better outcomes than other membranes. The patient outcomes include cardiovascular, respiratory, renal, and overall survivals, but this information of oXiris are insufficient. Although cytokine and endotoxin removal rates are great in oXiris, the beneficial effects on the hard outcomes are needed to use oXiris in real clinical practice. The inflammatory and cardiovascular systems have intensive crosstalk, and thus if there are remission in inflammatory process, the patients can have hemodynamic stability. Regarding this, the investigators would like to compare the hemodynamic stability between oXiris and other standard membrane such as polysulfone, using our new real-time monitoring registry.

Interventions

Perform continuous renal replacement therapy with oXiris membrane

Perform continuous renal replacement therapy with polysulfone membrane

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged ≥ 18 years * Sepsis related acute kidney injury requiring continuous renal replacement therapy

Exclusion criteria

• No monitoring of blood pressure and ECG

Design outcomes

Primary

MeasureTime frameDescription
Rate of all-cause mortality28 daysRisk of all-cause mortality
Occurrence rates of ventricular tachycardia, intradialytic hypotension28 daysRisk of ventricular tachycardia, intradialytic hypotension

Countries

South Korea

Contacts

Primary ContactSeung Seok Han, M.D.
hansway7@snu.ac.kr82-2-2072-4785
Backup ContactDonghwan Yun, M.D.
dactylogram@snu.ac.kr82-10-9385-6727

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026